TargetMol

Monomethyl lithospermate

Product Code:
 
TAR-TN3323
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-TN3323-1mg1mg£358.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-TN3323-5mg5mg£777.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
Monomethyl lithospermate has potential antiviral activity, alleviating ischemic stroke injury in vivo in middle cerebral artery occlusion mice by activating PI5K/Akt signaling and protecting oxygen-glucose deprivation/reoxygenation-induced SHSY-3Y cells in vitro. Monomethyl lithospermate could improve the viability of SHSY-5Y cells, inhibit mitochondrial membrane potential (MMOP) collapse, and inhibit cell apoptosis. Monomethyl lithospermate also reduced the level of oxidative stress in the brain tissue of middle artery occlusion (MCAO) rats and improved nerve damage in ischemic stroke (IS) rats.
CAS:
933054-33-2
Formula:
C28H24O12
Molecular Weight:
552.5
Pathway:
PI3K/Akt/mTOR signaling|Cytoskeletal Signaling
Purity:
0.98
SMILES:
COC(=O)[C@@H]1[C@H](Oc2c1c(C=CC(=O)O[C@H](Cc1ccc(O)c(O)c1)C(O)=O)ccc2O)c1ccc(O)c(O)c1
Target:
PI3K|Akt

References

Yang F, et al. Monomethyl lithospermate alleviates ischemic stroke injury in middle cerebral artery occlusion mice in vivo and protects oxygen glucose deprivation/reoxygenation induced SHSY-5Y cells in vitro via activation of PI3K/Akt signaling. Front Pharmacol. 2022 Oct 13;13:1024439.